RAC.AX
Healthcare BiotechnologyRacura Oncology Ltd
A$1.93
+0.01 +0.52% today
Price History
Not enough data
Key Stats
Market Cap
378.41M
Avg Volume
81,322
EPS
-A$0.06
52W High
A$4.90
52W Low
A$1.84
Div. Yield
0.0%
Valuation
Forward P/E
-18.74
P/B Ratio
10.38
P/S Ratio
134.62
EV/EBITDA
-33.80
EV/Revenue
121.72
Margins
Gross Margin 61.2%
Operating Margin (370.1%)
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Revenue Growth (YoY)
(12.2%)
Return on Equity
(42.3%)
Return on Assets
(23.4%)
Liquidity & Leverage
Current Ratio
21.43
Quick Ratio
21.28
Total Cash
34.29M
Total Debt
0
About
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
racuraoncology.com